YAP silencing by RB1 mutation is essential for small-cell lung cancer metastasis
Zhengming Wu1, Junhui Su2, Fu-Long Li3
1Department of Pharmacology and Moores Cancer Center, University of California, San Diego, La Jolla, CA, 92093, USA.
Abstract:
Small cell lung cancer (SCLC) is highly lethal due to its prevalent metastasis. Most SCLCs have inactivating mutations in TP53 and RB1. We find that loss of YAP expression is key for SCLC cells to acquire rapid ameboid migration and high metastatic potential. YAP functions through its target genes CCN1/CCN2 to inhibit SCLC ameboid migration. RB1 mutation contributes to YAP transcriptional silencing via E2F7, which recruits the RCOR co-repressor complex to YAP promoter. We discover that benzamide family HDAC inhibitors stimulate YAP expression by inhibiting the RCOR-HDAC complex, thereby suppressing SCLC metastasis and improving survival in a mouse model. Our study unveils the molecular and cellular basis underlying SCLC's high metastatic potential, the previously unrecognized role of YAP in suppressing ameboid migration and tumor metastasis, and the mechanism of YAP transcription regulation involving E2F7, RCOR, and Sin3 HDAC. This study reveals a therapeutic potential of benzamides for SCLC treatment.
Insights
Loss of YAP expression drives small cell lung cancer (SCLC) metastasis. Benzamide HDAC inhibitors restore YAP, suppressing SCLC spread and improving survival in mice.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Metastasis
Background:
- Small cell lung cancer (SCLC) is characterized by high lethality due to frequent metastasis.
- Inactivating mutations in TP53 and RB1 are common in SCLC.
- The molecular mechanisms driving SCLC metastasis remain incompletely understood.
Purpose of the Study:
- To investigate the role of YAP expression in SCLC metastasis.
- To elucidate the regulatory mechanisms of YAP transcription in SCLC.
- To identify potential therapeutic strategies targeting SCLC metastasis.
Main Methods:
- Analysis of YAP expression in SCLC cells.
- Investigation of YAP target genes (CCN1/CCN2) and their role in migration.
- Study of RB1 mutation, E2F7, and RCOR complex interaction with the YAP promoter.
- Evaluation of benzamide family HDAC inhibitors in vitro and in a mouse model.
Main Results:
- Loss of YAP expression correlates with increased ameboid migration and metastatic potential in SCLC.
- YAP inhibits SCLC ameboid migration via CCN1/CCN2.
- RB1 mutations lead to YAP transcriptional silencing through E2F7 and RCOR recruitment.
- Benzamide HDAC inhibitors restore YAP expression by targeting the RCOR-HDAC complex, suppressing metastasis, and improving survival in mice.
Conclusions:
- YAP plays a critical role in suppressing SCLC ameboid migration and metastasis.
- The E2F7/RCOR/Sin3 HDAC complex mediates YAP transcriptional silencing in RB1-mutated SCLC.
- Benzamide HDAC inhibitors represent a promising therapeutic strategy for SCLC by restoring YAP expression and inhibiting metastasis.
More Related Videos
09:55All-optical Mechanobiology Interrogation of Yes-associated Protein in Human Cancer and Normal Cells using a Multi-functional System
Published on: December 20, 2021
11:32Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
Published on: March 27, 2020
Related Concept Videos
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Abnormal Proliferation
Negative Regulator Molecules
The Ras Gene
Ras is a...
MicroRNAs
Experimental RNAi
